Sign in
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2020
Category: AMD-Non-Neovascular